Comparison · NCT01802775-7d37a480
Clopidogrel vs Edoxaban: Number of Participants With Amputations
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Clopidogrel vs Edoxaban: Number of Participants With Amputations. Trial comparisons, record NCT01802775-7d37a480. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01802775-7d37a480
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0297 | 0.0102 | 0.0837 | wilson | |
| Risk in group 2 | 0.01 | 0.00177 | 0.0545 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0197 | -0.0289 | 0.0743 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.97 | 0.314 | 28.1 | log | |
| Odds ratio, group 1 over group 2 | 3.03 | 0.31 | 29.6 | log | |
| Number needed to treat, for one more participant with the outcome on Clopidogrel than on Edoxaban | 50.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Clopidogrel | Open-label clopidogrel with aspirin | 3 | 101 | OG000 |
| Group 2 | Edoxaban | Open-label edoxaban with aspirin | 1 | 100 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Amputations
- Description
- Number of participants with amputations within 6 months
- Time frame
- within 6 months
- Population
- Safety Analysis Set
Source ClinicalTrials.gov
Trial
- Title
- Edoxaban in Peripheral Arterial Disease
- NCT number
- NCT01802775
- Phases
- PHASE2
- Conditions
- Peripheral Arterial Disease
- Interventions
- edoxaban, Clopidogrel, Aspirin
- Lead sponsor
- Daiichi Sankyo
- Results first posted
- 2018-01-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01802775?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01802775-7d37a480